40 articles for G Siemeister
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Optimization of allosteric MEK inhibitors. Part 2: Taming the sulfamide group balances compound distribution properties.

Bayer Healthcare
Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors.

Novartis Pharma
Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction.

Bayer AG
Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity.

Bayer Pharma AG
Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer.

Bayer Pharma
BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies.

Bayer
Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase.

Bayer
Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models.

Bayer
Optimization of allosteric MEK inhibitors. Part 1: Venturing into underexplored SAR territories.

Bayer Healthcare
AMIDE-CONTAINING LONP1 INHIBITOR COMPOUNDS, USES AND METHODS

Pretzel Therapeutics
CRYSTAL FORM OF PYRROLOPYRIMIDINE COMPOUND AND PREPARATION METHOD FOR CRYSTAL FORM

Zhejiang Longcharm Bio-Tech Pharma. Co.
Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine

Kronos Bio
Substituted [5,6]cyclic-4(3H)-pyrimidinones as anticancer agents

Zenji Research Laboratories
Imidazolepyridine compounds and uses thereof

Novartis
Tricyclic PI3K inhibitor compounds and methods of use

Genentech
Triaza-spirodecanones as DDR1 inhibitors

Hoffmann-La Roche
GLS1 inhibitors for treating disease

The University of Texas System
Piperidine isoxazole and isothiazole orexin receptor antagonists

Merck Sharp & Dohme
Cinnoline derivatives useful as CB-1 receptor inverse agonists

Janssen Pharmaceutica
5-azaindazole compounds and methods of use

F. Hoffmann-La Roche
Sulfapyridine-like benzenesulfonamide derivatives as inhibitors of carbonic anhydrase isoenzymes I, II and VI.

Ataturk University
Design, synthesis, and urease inhibition studies of some 1,3,4-oxadiazoles and 1,2,4-triazoles derived from mandelic acid.

Quaid-I-Azam University
Heat Capacity Changes for Transition-State Analogue Binding and Catalysis with Human 5'-Methylthioadenosine Phosphorylase.

Albert Einstein College of Medicine
3,4-dihydropyrrolo[1,2-A]pyrazine-2,8(1H)-dicarboxamide derivatives, preparation thereof and therapeutic use thereof for diseases involving casein kinase 1 epsilon and/or casein kinase 1 delta

Sanofi
Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof

Kissei Pharmaceutical
Design, synthesis, biological evaluation, and molecular docking of novel benzopyran and phenylpyrazole derivatives as Akt inhibitors.

Zhejiang University
Selective androgen receptor modulators

Radius Health
Heterocyclic derivatives

Novartis
Triazinoindole analogs as potent inhibitors of a-glucosidase: synthesis, biological evaluation and molecular docking studies.

Hazara University
Heterocyclic compounds and uses thereof

Celgene Avilomics Research
Selective glycosidase inhibitors and uses thereof

Simon Fraser University
Bicyclic compounds and their uses as dual c-SRC/JAK inhibitors

Debiopharm
Histone deacetylase inhibitors, process for preparation and uses thereof

Zhejiang Hisun Pharmaceutical
Macrocyclic inhibitors of hepatitis C virus

Medivir
Urokinase inhibitors, production and use thereof

The Medicines
Stable expression of a synthetic gene for the human motilin receptor: use in an aequorin-based receptor activation assay.

Kosan Biosciences
Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding.

Gsk